Accepted Manuscript

MIR21 drives resistance to Heat Shock Protein 90 inhibition in cholangiocarcinoma

Andrea Lampis, Pietro Carotenuto, Georgios Vlachogiannis, Luciano Cascione, Somaieh Hedayat, Rosemary Burke, Paul Clarke, Else Bosma, Michele Simbolo, Aldo Scarpa, Sijia Yu, Rebecca Cole, Elizabeth Smyth, Javier Fernández Mateos, Ruwaida Begum, Blanka Hezelova, Zakaria Eltahir, Andrew Wotherspoon, Nicos Fotiadis, Maria Antonietta Bali, Chirag Nepal, Khurum Khan, Mark Stubbs, Jens C. Hahne, Pierluigi Gasparini, Vincenza Guzzardo, Carlo M. Croce, Suzanne Eccles, Matteo Fassan, David Cunningham, Jesper B. Andersen, Paul Workman, Nicola Valeri, Chiara Braconi



 PII:
 S0016-5085(17)36331-X

 DOI:
 10.1053/j.gastro.2017.10.043

 Reference:
 YGAST 61519

To appear in: *Gastroenterology* Accepted Date: 27 October 2017

Please cite this article as: Lampis A, Carotenuto P, Vlachogiannis G, Cascione L, Hedayat S, Burke R, Clarke P, Bosma E, Simbolo M, Scarpa A, Yu S, Cole R, Smyth E, Mateos JF, Begum R, Hezelova B, Eltahir Z, Wotherspoon A, Fotiadis N, Bali MA, Nepal C, Khan K, Stubbs M, Hahne JC, Gasparini P, Guzzardo V, Croce CM, Eccles S, Fassan M, Cunningham D, Andersen JB, Workman P, Valeri N, Braconi C, MIR21 drives resistance to Heat Shock Protein 90 inhibition in cholangiocarcinoma, *Gastroenterology* (2017), doi: 10.1053/j.gastro.2017.10.043.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

ACCEPTED MANUSCRIPT

MIR21 drives resistance to Heat Shock Protein 90 inhibition in cholangiocarcinoma.

Short title: MIR21 as biomarker of resistance to HSP90 inhibition

Andrea Lampis¹, Pietro Carotenuto¹, Georgios Vlachogiannis¹, Luciano Cascione², Somaieh Hedayat¹, Rosemary Burke¹, Paul Clarke¹, Else Bosma¹, Michele Simbolo³, Aldo Scarpa³, Sijia Yu¹, Rebecca Cole¹, Elizabeth Smyth⁴, Javier Fernández Mateos¹, Ruwaida Begum⁴, Blanka Hezelova⁴, Zakaria Eltahir⁴, Andrew Wotherspoon⁴, Nicos Fotiadis⁴, Maria Antonietta Bali⁴, Chirag Nepal⁵, Khurum, Khan⁴, Mark Stubbs¹, Jens C Hahne¹, Pierluigi Gasparini⁶, Vincenza Guzzardo⁷, Carlo M Croce⁶, Suzanne Eccles¹, Matteo Fassan^{3,7}, David Cunningham⁴, Jesper B Andersen⁵, Paul Workman¹, Nicola Valeri^{1,4}, Chiara Braconi^{1,4}

¹ The Institute of Cancer Research, London, UK

² Bioinformatics Core Unit, Institute of Oncology Research, Bellinzona, Switzerland

³ ARC-Net Research Centre and Department of Pathology and Diagnostics, University of Verona, Verona, IT

⁴ The Royal Marsden NHS Trust London and Surrey, UK

⁵ Biotech Research and Innovation Centre, Department of Health and Medical Sciences, University of Copenhagen, Copenhagen, DK

⁶Ohio State University, Columbus, USA

⁷ Department of Medicine, University of Padua, Padua, IT

Contact Information: Chiara Braconi, Division of Cancer Therapeutics at The Institute of Cancer Research, London SM2 5NG. Phone: 0044 (0)2087224526. Fax: 0044 (0)2087224301 Email: <u>Chiara.braconi@icr.ac.uk</u>.

Conflict of interest: PW and SE are members of the Project Team at ICR that developed AUY922 in collaboration with Vernalis.

Transcriptomic profiling: nanostring PDO (GEO accession number GSE102064)

Writing assistance: we thank Nicky Evans for her editorial support

Author contribution: study concept and design (CB); acquisition of data (AL, PC, GV, SH, EB, MS, SY, RC, JFM, ZE, CN, JCH, PG, MF, VG); analysis and interpretation of data (LC,

Download English Version:

https://daneshyari.com/en/article/8726942

Download Persian Version:

https://daneshyari.com/article/8726942

Daneshyari.com